Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload

Hematology (United Kingdom)

Volumn 20, Issue 5, 2015, Pages 304-310

  Chen, Cheng Hsu ^a,b,c   Shu, Kuo Hsiung ^a,d   Yang, Youngsen ^a,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b TUNGHAI UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Deferasirox; End stage renal disease; Iron chelator; Iron overload; Renal anemia

Indexed keywords

DEFERASIROX; ERYTHROPOIETIN; FERRITIN; TRANSFERRIN; ELECTROLYTE; IRON; PARATHYROID HORMONE; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMATOPOIESIS; HEMODIALYSIS; HUMAN; IRON BINDING CAPACITY; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; THORAX PAIN; TREATMENT RESPONSE; VOMITING; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; END STAGE RENAL DISEASE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS PATIENT; SKIN DEFECT; ADVERSE EFFECTS; ANEMIA; BLOOD; CHELATION THERAPY; COMPLICATION; ORAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; BENZOATES; BLOOD TRANSFUSION; CHELATION THERAPY; FEMALE; HEMATOPOIESIS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84929155200     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000199     Document Type: Article

References (40)

1. Ifudu O, Macey LJ, Friedman EA. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients. ASAIO J. 1995;41:M426–30.
2. Tanhehco YC, Berns JS. Red blood cell transfusion risks in patients with end-stage renal disease. Semin Dial. 2012;25: 539–44.
3. Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology 2012;115:635–49.
4. Menis M, Izurieta HS, Anderson SA, Kropp G, Holness L, Gibbs J, et al. Outpatient transfusions and occurrence of serious noninfectious transfusion-related complications among US elderly, 2007–2008: utility of large administrative databases in blood safety research. Transfusion 2012;52:1968–76.
5. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17:120–62.
6. Agarwal R. Individualizing decision-making – resurrecting the doctor-patient relationship in the anemia debate. Clin J Am Soc Nephrol. 2010;5:1340–6.
7. Winchester JF. Management of iron overload in dialysis patients. Semin Nephrol. 1986;6(Suppl 1):22–6.
8. Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, et al. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1089–97.
9. Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminum chelating drugs. Toxicol Lett. 1995;80:1–18.
10. Kan WC, Chien CC, Wu CC, Su SB, Hwang JC, Wang HY. Comparison of low-dose deferoxamine versus standarddose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010; 25:1604–8.
11. Agarwal MB. Deferasirox: oral, once daily iron chelator – an expert opinion. Indian J Pediatr. 2010;77:185–91.
12. Taher A. Iron overload in thalassemia and sickle cell disease. Semin Hematol. 2005;42:S5–9.
13. Cancado R, Olivato MC, Bruniera P, Szarf G, de Moraes Bastos R, Rezende Melo M, et al. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients. Acta Haematol. 2012;128: 113–8.
14. Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebocontrolled study. Blood 2012;120:970–7.
15. List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30:2134–9.
16. Hohneker JA. Exjade (deferasirox): boxed warning. In: MedWatch: The FDA Safety Information and Adverse Event Reporting Program, 2010.
17. Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25:2376–8.
18. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455–62.
19. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. [Accessed 2013 May 20] Common terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009; Revised Version 4.03 June 14, 2010 (Vol. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5×7.pdf).
20. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2(Suppl): 279–335.
21. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, et al. Evidence for tissue iron overload in longterm hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87–93.
22. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803–11.
23. Heath AL, Fairweather-Tait SJ. Health implications of iron overload: the role of diet and genotype. Nutr Rev. 2003;61:45–62.
24. Sengoelge G, Sunder-Plassmann G, Hörl WH. Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr. 2005;15:105–10.
25. Yamamoto H, Tsubakihara Y. Limiting iron supplementation for anemia in dialysis patients – the Basis for Japan’s conservative guidelines. Semin Dial. 2011;24:269–71.
26. Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002; 17(Suppl 2):25–9.
27. Deira J, Diego J, Martínez R, Oyarbide A, González A, Díaz H, et al. Comparative study of intravenous ascorbic acid versus lowdose desferrioxamine in patients on hemodialysis with hyperferritinemia. J Nephrol. 2003;16:703–9.
28. Tsai CW, Yang FJ, Huang CC, Kuo CC, Chen YM. The administration of deferasirox in an iron-overloaded dialysis patient. Hemodial Int. 2012;17:131–3.
29. Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynyk JK. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton). 2013;18:188–93.
30. Cappellini MD. Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag. 2007;3:291–9.
31. Yusuf B, McPhedran P, Brewster UC. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis. 2008;52:587–90.
32. Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, et al. Deferasirox treatment for myelodysplastic syndromes: ‘real-life’ efficacy and safety in a single-institution patient population. Ann Hematol. 2012;91:1345–9.
33. Aucella F, Vigilante M, Scalzulli P, Musto P, Crisetti A, Modoni S, et al. Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients. Nephrol Dial Transplant. 1998;13:1194–9.
34. Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95: 1308–16.
35. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97(9):1364–71.
36. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94(2):288–99.
37. Vreugdenhil G, Smeets M, Feelders RA, van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in ironloading anaemia. Acta Haematol. 1993;89(2):57–60.
38. Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92(2):191–8.
39. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70–4.
40. Garadah TS, Mahdi N, Kassab S, Abu-Taleb A, Shoroqi I, Alawadi AH. The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major. Eur J Haematol. 2011;87:267–73.